PopCheck Technologies

Cover Block

Attribute	Value
Company Name	PopCheck Technologies
Tagline	AI-enabled remote postoperative monitoring platform with wearable to predict and prevent venous blood clots.
Headquarters	Memphis, United States
Founded	2021
Stage	Pre-Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Pre-seed
Total Disclosed Funding	~$1,520,000

Links

• Website: https://popchecktechnologies.com/about-us.php
• LinkedIn: https://www.linkedin.com/company/popcheck-technologies-inc

Summary and Signal

PopCheck Technologies is a pre-seed digital health startup developing an FDA-pending wearable and AI platform to predict venous blood clots in post-surgical patients, a high-cost, high-mortality problem where predictive tools are scarce [PopCheck Technologies]. The company's core wedge is a physician-founded focus on venous thromboembolism (VTE) prevention, combining a non-invasive wearable with a digital platform that alerts care teams to biomarker patterns suggestive of clot formation before symptoms appear [PopCheck Technologies, CB Insights]. Founder and CEO Dr. Erika Dillard, a physician-scientist with neurosurgery and intensive care training, conceived the idea while managing post-operative patients, providing a direct founder-market fit [Science Center, Venture Cafe Philadelphia].

To date, the company has disclosed approximately $1.52 million in pre-seed capital, sourced largely from a network of regional accelerators and grant programs including MedTech Innovator, Launch Tennessee, and the University City Science Center [CB Insights, PitchBook]. The business model targets hospitals and surgical centers, aiming to reduce preventable readmissions through at-home monitoring. Over the next 12-18 months, the key milestones to watch are the progression of reported hospital pilots into commercial contracts and the accumulation of clinical validation data for the AI prediction algorithm.

Data Accuracy: YELLOW -- Core company claims and founder background are confirmed; funding details are partially corroborated by multiple databases but lack full round-level disclosure.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Pre-seed (total disclosed ~$1,520,000)

Company Overview

PopCheck Technologies was founded in 2021 by Dr. Erika Dillard, a physician-scientist who left a neurosurgery residency to build a solution for a problem she managed directly: the risk of venous thromboembolism after surgery [Science Center]. The company is headquartered in Memphis, Tennessee [Venture Cafe Philadelphia, Technical.ly]. Its legal entity is PopCheck Technologies, Inc., registered at 460 South Highland Street in Memphis [F6S].

Key milestones follow a path typical for a regulated medical device startup. The company secured early non-dilutive grant funding, including a LaunchTN grant in late 2021 [University of Memphis, September 2021]. It then progressed through a series of accelerator programs, including MedTech Innovator and the University City Science Center's programming [CB Insights]. A significant technical milestone will be achieved when its core wearable product, VenaCheck, receives 510(k) clearance from the FDA, a prerequisite for commercial deployment in the U.S. market.

Data Accuracy: YELLOW -- Core founding details are consistent across multiple sources, but specific milestone dates and entity details are not fully corroborated by primary state filings.

The Product and the Stack

PopCheck Technologies is building a hardware-software system aimed at a specific, high-cost surgical complication. The company’s VenaCheck wearable is designed to be worn by patients after major surgeries like total joint replacements. The device monitors physical biomarker patterns, a process the company describes as non-invasive, and incorporates external muscle stimulation intended for clot prevention [PopCheck Technologies] [F6S]. The data streams to a connected digital platform where proprietary algorithms analyze the patterns to generate risk alerts for healthcare teams, framing the solution as a predictive early-warning system rather than a retrospective monitor.

Data Accuracy: YELLOW -- Core product claims are from company and database sources; technical implementation and performance metrics are not independently verified.

The Market They Are Entering

PopCheck Technologies operates at the intersection of remote patient monitoring (RPM) and medical-grade wearables. The global remote patient monitoring market was valued at approximately $53.6 billion in 2023 and is projected to grow at a compound annual rate of over 20% through 2030 [Grand View Research, 2024]. The market for venous thromboembolism prevention devices was estimated at $3.4 billion in 2022 [GlobalData, 2023]. PopCheck's SAM would be a subset of this, targeting high-risk surgical patients, particularly the over one million total joint replacement procedures performed annually in the United States alone [American Academy of Orthopaedic Surgeons, 2023].

Metric	Value
Global RPM Market 2023	$53.6B
VTE Prevention Devices 2022	$3.4B

Data Accuracy: YELLOW -- Market sizing figures are from third-party analyst reports but are for analogous, broader markets. Specific TAM for predictive VTE wearables is not publicly available.

The Competitive Field

PopCheck Technologies enters a healthcare segment where competition is defined by a split between established medical device incumbents, a wave of digital health software platforms, and a small cluster of startups targeting specific physiological monitoring.

Company	Positioning	Stage / Funding	Notable Differentiator
PopCheck Technologies	AI-enabled remote monitoring for post-surgical VTE prediction and prevention via wearable (VenaCheck) and digital platform.	Pre-seed (~$1.52M).	Wearable combining biomarker pattern recognition with muscle stimulation for both prediction and prevention of clots.
BioIntelliSense	Continuous, multi-parameter vital signs monitoring for hospital-to-home care transitions, targeting a wide range of conditions.	Later-stage; raised $45M Series B in 2021.	FDA-cleared BioButton wearable for 30-day continuous monitoring of temperature, heart rate, respiratory rate, and more.

Data Accuracy: YELLOW -- Competitor funding and positioning are from public databases; PopCheck's differentiation claims are sourced from the company and industry profiles.

Opportunity

If PopCheck Technologies can successfully deploy its predictive monitoring system across the high-risk surgical population it targets, the company could capture a significant share of a multi-billion-dollar market defined by the cost of preventable hospital readmissions. The headline opportunity for PopCheck is to establish the clinical standard for at-home venous thromboembolism (VTE) risk management following major surgery [PopCheck Technologies].

Data Accuracy: YELLOW -- The market size and cost data are inferred from a single local news report. The growth scenarios are logical extrapolations from the company's stated focus and regulatory status, but lack public confirmation of active pilots or contracts.

Where We Land

Verdict: PASS / WATCH / PROCEED,... Conviction:... Time horizon:...

Agentic / AI relevance

Sources

1. [PopCheck Technologies] PopCheckTechnologies | https://popchecktechnologies.com/about-us.php
2. [CB Insights] CB Insights Company Profile | https://www.cbinsights.com/company/popcheck
3. [Science Center] The Rise of the Physician-Entrepreneur: Erika Dillard of PopCheck Technologies | https://sciencecenter.org/blog/the-rise-of-the-physician-entrepreneur-erika-dillard-of-popcheck-technologies
4. [Venture Cafe Philadelphia] Erika Dillard's Story | https://venturecafephiladelphia.org/stories/erika-dillard/
5. [University of Memphis, September 2021] UofM’s Collaborative Startup, PopCheck Technologies, Secures LaunchTN Grant | https://www.memphis.edu/research/impact/newsletter_2021/september_stories/umcollaborativestartup.php
6. [Technical.ly] This founder left Philly for Memphis. University City Science Center still calls her startup's growth a win | https://technical.ly/startups/university-city-science-center-popcheck-technologies/
7. [F6S] F6S Company Profile | https://www.f6s.com/company/popcheck-technologies-inc
8. [PitchBook] PitchBook Company Profile | https://pitchbook.com/profiles/company/489428-47
9. [Crunchbase, October 2021] BioIntelliSense Raises $45M Series B | https://www.crunchbase.com/organization/biointellisense
10. [Grand View Research, 2024] Remote Patient Monitoring Market Report | https://www.grandviewresearch.com/industry-analysis/remote-patient-monitoring-market
11. [GlobalData, 2023] Venous Thromboembolism Prevention Devices Market Report | https://www.globaldata.com/store/report/venous-thromboembolism-prevention-devices-market-analysis/
12. [American Academy of Orthopaedic Surgeons, 2023] Joint Replacement Statistics | https://www.aaos.org/news/aaosnow/apr23/clinical/clinical10/
13. [Agency for Healthcare Research and Quality] Healthcare Cost and Utilization Project (HCUP) | https://www.ahrq.gov/data/hcup/index.html
14. [Centers for Medicare & Medicaid Services] Medicare Remote Patient Monitoring Reimbursement | https://www.cms.gov/medicare/medicare-fee-for-service-payment/physicianfeesched
15. [Memphis Business Journal, June 2025] Memphis startup's wearable tech aims to rework post-surgical venous clot monitoring | https://www.bizjournals.com/memphis/news/2025/06/06/popcheck-technologies-sba-emerging-entrepreneurs.html